Archive for December, 2011

Billionaire Philip Falcone’s hedge fund, Harbinger Capital Partners, has been told it may be sued by regulators for securities-law violations and says it plans to halt investor withdrawals at year-end.

Falcone, 49, and other Harbinger employees also received Wells Notices from the staff of the Securities and Exchange Commission, Harbinger said in a filing last week.

A lawsuit would add to Falcone’s woes, as assets at his $5.7 billion fund have slumped from a peak of $26 billion three years ago and a wireless tech venture he’s backing faces regulatory and political hurdles. New York-based Harbinger is being investigated by the SEC over a $113 million loan Falcone took from one of his funds to pay personal taxes, according to a July filing.

Harbinger told clients in April that the government was also looking into whether it had engaged in market manipulation in its trading of the debt securities of an undisclosed firm from 2006 and 2008.

“Harbinger and its affiliates are disappointed that the staff issued Wells Notices,” the firm said in the filing. “If the SEC decides to bring an enforcement action,” they “intend to vigorously defend against it.”

The SEC declined to comment.

Hedge funds are much more experienced in picking stocks than ordinary investors. They have a group of smart professionals who have years of experience in investments to research the market and the stocks. Sometimes they are even able to obtain material non-public information and make trades on the information. For ordinary investors who do not want to pay the expensive hedge fund fees or aren’t wealthy enough to qualify, imitating hedge funds’ most popular stock picks is a great strategy. According to our studies, this strategy beats the market on the average by 2 percentage points annually.

Below we compiled a list of healthcare stocks that hedge funds are most bullish about. The data is gathered from Goldman Sachs’ hedge funds report and show the hedge fund holdings as of September 30.

Ticker Company No. of HFs % of Equity Cap owned by HFs
JNJ Johnson & Johnson 14 1
PFE Pfizer Inc. 29 2
VRX Valeant Pharmaceuticals International, Inc. 14 16
WLP WellPoint Inc. 15 8
CVS CVS Caremark 14 5

Pfizer Inc (PFE) is the healthcare stock that most hedge funds are bullish about. It was owned by 29 hedge funds and 2% of its equity cap is in the hands of hedge funds. The drug manufacturer has a market cap of $153B and a P/E ratio of 15.62. It was up about 10% since the beginning of this year. Ken Fisher was bullish about PFE. His Fisher Asset Management reported to own nearly $400 million worth of PFE stocks as of September 30th.

Valeant Pharmaceuticals International Inc (VRX) has the largest percentage of its equity owned by hedge funds. Hedge funds own 16% of the outstanding shares of this drug delivery company. VRX has a market cap of $13.8B and a P/E ratio of 220.86. It returned around 48% since the beginning of this year. There are 14 hedge funds bullish about VRX as of September 30. Andreas Halvorsen’s Viking Global had more than $300 million invested in this stock.

WellPoint Inc (WLP) is also very popular among hedge funds. As of September 30, there are 15 hedge funds owning 8% of the equity cap of WellPoint. WLP has a market cap of $23.8B and a relatively low P/E ratio of 8.99. WLP returned 14% so far this year.

Johnson & Johnson (JNJ), the mega cap company, was owned by 14 different hedge funds at the end of the third quarter. One percent of its equity cap was owned by these 14 hedge funds. It returned approximately 3% since the beginning of this year. JNJ has a market cap of $173B and a P/E ratio of 15.45. Among the 14 hedge funds owned JNJ, Warren Buffett’s Berkshire Hathaway had the biggest position. The fund had $2.4 billion invested in Johnson & Johnson.

CVS Caremark (CVS) was owned by 14 hedge funds as a top 10 stock holding. Hedge funds owned 5% of its outstanding shares. CVS is more popular than its rivals Express Scripts (ESRX) and Medco Health Solutions (MHS). ESRX proposed to acquire MHS for $29 billion but the merger is facing intensified scrutiny from lawmakers. If this merger proceeds the merged company will be nearly twice as big as CVS. CVS has a forward PE ratio of 14 and is expected to increase its earnings by around 11% annually over the next five years. CVS returned 12% so far this year.

Healthcare is a fast-growing industry in the United States. National Health Expenditures (NHE) as a share of GDP is expected to be 19.6% by 2019, based on our projections of NHE for the next 10 years. The five healthcare stocks on the list above generated positive better than market return so far this year. As the spending and costs for healthcare are rising, we believe healthcare stocks will remain in the portfolio of hedge funds, and we recommend investors to focus on the healthcare stocks that are popular among hedge funds.

Source : seekingalpha

Raj Rajaratnam, who started the hedge fund Galleon Group, begins his 11-year sentence in Massachusetts after his conviction for insider trading.

DEVENS, Mass. — The hedge fund founder handed the longest prison term ever given for insider trading reported Monday to a federal facility in Massachusetts to begin serving his 11-year sentence.

Raj Rajaratnam, who started the hedge fund Galleon Group, reported to the Federal Medical Center here, U.S. Bureau of Prisons spokeswoman Traci Billingsley said. The prison for men is located about 40 miles west of Boston. The facility on decommissioned military base Fort Devens houses inmates who require specialized or long-term medical or mental health care.

The Sri Lanka native and onetime billionaire lost his last-minute effort last week to get a federal appeals court to let him remain free pending appeal. He was convicted in May of trading on inside information from 2003 through 2009.

Prosecutors said he made more than $70 million in illegal profits in an insider trading scheme that enlisted friends and associates in the hedge fund industry and at public companies to provide inside information about earnings, mergers and acquisitions.

The 54-year-old Rajaratnam had asked for leniency because of health problems, which include diabetes, sleep apnea and high blood pressure. His sentence, though the longest in history for insider trading, was about half of what the government had sought.
Source: LA times
Prosecutors had called the case against Rajaratnam the biggest insider trading investigation in history. It resulted in the convictions of more than two dozen people and led to a spinoff probe of Wall Street researchers who enabled corrupt public company employees to pass along inside information as legitimate research to hedge fund managers. The investigation also made unprecedented use of wiretaps, allowing jurors at Rajaratnam’s trial to hear dozens of taped conversations between Rajaratnam and co-conspirators.